Cost Effectiveness Analysis of Pirfenidone For The Treatment of Mild To Moderate Idiopathic Pulmonary Fibrosis (IPF) Compared To Best Supportive Care And Nintedanib From The Italian NHS Perspective
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1211
https://www.valueinhealthjournal.com/article/S1098-3015(16)32577-3/fulltext
Title :
Cost Effectiveness Analysis of Pirfenidone For The Treatment of Mild To Moderate Idiopathic Pulmonary Fibrosis (IPF) Compared To Best Supportive Care And Nintedanib From The Italian NHS Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32577-3&doi=10.1016/j.jval.2016.09.1211
First page :
A556
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1135